Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Evotec SE's gross profit for the
three
months ended in Mar. 2026 was CHF-1.4 Mil. Evotec SE's gross profit for the trailing twelve months (TTM) ended in Mar. 2026 was CHF79.8 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Evotec SE's gross profit for the
three
months ended in Mar. 2026 was CHF-1.4 Mil. Evotec SE's Revenue for the
three
months ended in Mar. 2026 was CHF142.6 Mil. Therefore, Evotec SE's Gross Margin % for the quarter that ended in Mar. 2026 was -1.00%.
Evotec SE had a gross margin of -1.00% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
During the past 13 years, the highestGross Margin % of Evotec SE was 35.59%. The lowest was 11.47%. And the median was 24.81%.
Warning Sign:
Evotec SE gross margin has been in long-term decline. The average rate of decline per year is -11.8%.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Evotec SE had a gross margin of -1.00% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
Evotec SE Gross Profit Related Terms
Evotec SE Gross Profit Historical Data
* Premium members only.
The historical data trend for Evotec SE's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:EVT vs ZTS, UTHR, VTRS: Gross Profit Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Evotec SE's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evotec SE Gross Profit vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Evotec SE's Gross Profit distribution charts can be found below:
* The bar in red indicates where Evotec SE's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF79.8 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Evotec SE (XSWX:EVT) has a Gross Profit of CHF79.8 Mil as of Mar. 2026. Gross Profit equals net sales less total cost of goods sold. View historical data on Evotec SE and its competitors.
Is Evotec SE's Gross Profit too high?
Evotec SE's current Gross Profit is CHF79.8 Mil. Overall, Evotec SE has a GF Score™ of 58/100, reflecting its overall financial health beyond just this single metric.
How does Evotec SE's Gross Profit compare to ZTS and UTHR?
Evotec SE's Gross Profit of CHF79.8 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Drug Manufacturers company?
A good Gross Profit depends on the Drug Manufacturers industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on Evotec SE and its competitors. Evotec SE's current Gross Profit is CHF79.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evotec SE stock overvalued right now?
Evotec SE (XSWX:EVT) has a current Gross Profit of CHF79.8 Mil. The stock's GF Value™ is CHF8.56, compared to a current price of CHF4.63 — trading 45.9% below its estimated fair value. The current Gross Profit is CHF79.8 Mil. Evotec SE's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For Evotec SE (XSWX:EVT), the current Gross Profit is CHF79.8 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Evotec SE (XSWX:EVT) Overvalued in 2026?
Based on GuruFocus' analysis, Evotec SE stock appears to be undervalued.
The current stock price of CHF4.63 is trading 45.9% below its estimated GF Value™ of CHF8.56.
Key valuation signals for XSWX:EVT:
Gross Profit: CHF79.8 Mil
GF Value™: CHF8.56 vs. price of CHF4.63 (45.9% below fair value)
No single metric tells the full story. See the XSWX:EVT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
58GF Score
Get the complete analysis for XSWX:EVT
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:EVT has been successfully added to your 
